Skip to main content
. 2019 Feb 6;11(3):463–476. doi: 10.1080/19420862.2019.1565748

Figure 4.

Figure 4.

Structural changes revealed from DEPC CL-MS experiments are validated using rituximab activity assays. The structural integrity of the Fc region is evaluated by (a) a rituximab bridging ELISA that measures Fc binding to a capture antibody and (b) an Alamar blue assay that measures complement dependent cytotoxicity (CDC). The structural integrity of the Fab region is assessed by (c) a Raji cell pull-down assay that measures Fab binding to CD20 antigen on B cells. For each temperature condition, the means of two groups i.e. stressed vs. control (37°C) were compared using student t-test at 95% confidence level. Each assay was performed in triplicate (n = 3).